Outlook Therapeutics, Inc. (OTLK)Healthcare | Biotechnology | Iselin, United States | NasdaqCM
0.47 USD
-0.09
(-16.602%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 0.49 +0.02 (3.764%) ⇧ (Oct. 14, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:08 a.m. EDT
The fundamental reality for Outlook Therapeutics is catastrophic: the company has endured nine consecutive years of decline, with the last four being negative, erasing over 99% of its value since the start of the observation window. Despite recent FDA approvals for its drug candidates, the financials tell a dire story of negative revenue, massive cash burn, and a balance sheet that cannot sustain operations without external capital. The market has already priced in this failure, reflected in the crushing long-term rating. While the stock recently rallied on regulatory wins, the immediate technical picture is weak, trading well below its moving averages, and the options chain is screaming 'sell,' with investors loading up on cheap insurance against further drops. There is no dividend to provide income, and the lack of a viable path to profitability makes any bounce a dangerous trap for long-term capital preservation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.139882 |
| MSTL | 0.264255 |
| AutoTheta | 0.302170 |
| AutoARIMA | 2.546948 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 0.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.004 |
| Excess Kurtosis | 0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | -0.014 |
| Market Cap | 114,469,040 |
| Forward P/E | -3.92 |
| Beta | 0.67 |
| Website | https://outlooktherapeutics.com |
As of Oct. 10, 2026, 4:08 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls across multiple expirations. The put/call ratio is skewed significantly toward selling, with deep out-of-the-money strikes showing notable volume, suggesting a fear of further collapse rather than a bet on recovery. Implied volatility is elevated on the downside side, indicating the market prices in significant uncertainty and potential further declines.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5791045 |
| Address1 | 111 S. Wood Avenue |
| Address2 | Unit #100 |
| All Time High | 878.4 |
| All Time Low | 0.161 |
| Ask | 0.6113 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 4,701,820 |
| Average Daily Volume3 Month | 13,017,277 |
| Average Volume | 13,017,277 |
| Average Volume10Days | 4,701,820 |
| Beta | 0.674 |
| Bid | 0.47 |
| Bid Size | 1 |
| Book Value | -0.056 |
| City | Iselin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4702 |
| Current Ratio | 0.808 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.5651 |
| Day Low | 0.47 |
| Display Name | Outlook Therapeutics |
| Dividend Date | 1,552,867,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,710,600 |
| Earnings Call Timestamp Start | 1,786,710,600 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda | -55,531,736 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.191 |
| Enterprise To Revenue | -104.564 |
| Enterprise Value | 121,658,112 |
| Eps Current Year | -0.435 |
| Eps Forward | -0.12 |
| Eps Trailing Twelve Months | -0.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.70152 |
| Fifty Day Average Change | -0.23132002 |
| Fifty Day Average Change Percent | -0.32974115 |
| Fifty Two Week Change Percent | -57.91045 |
| Fifty Two Week High | 2.538 |
| Fifty Two Week High Change | -2.0678 |
| Fifty Two Week High Change Percent | -0.814736 |
| Fifty Two Week Low | 0.161 |
| Fifty Two Week Low Change | 0.3092 |
| Fifty Two Week Low Change Percent | 1.9204968 |
| Fifty Two Week Range | 0.161 - 2.538 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,465,911,000,000 |
| Float Shares | 197,815,744 |
| Forward Eps | -0.12 |
| Forward P E | -3.9183335 |
| Free Cashflow | -37,357,632 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Fullday Change | -0.081799984 |
| Fullday Change Percent | -14.508689 |
| Fullday Price | 0.4702 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -2,275,914 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12639 |
| Held Percent Institutions | 0.16699 |
| Implied Shares Outstanding | 243,447,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,710,374,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. |
| Long Name | Outlook Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 114,469,040 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_145859589 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -61,123,256 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 161,089,246 |
| Number Of Analyst Opinions | 4 |
| Open | 0.5601 |
| Operating Cashflow | -56,154,884 |
| Operating Margins | -1,242.5527 |
| Phone | 609 619 3990 |
| Post Market Change | 0.017699987 |
| Post Market Change Percent | 3.7643528 |
| Post Market Price | 0.4879 |
| Post Market Time | 1,792,022,380 |
| Previous Close | 0.5638 |
| Price Eps Current Year | -1.0809195 |
| Price Hint | 4 |
| Price To Book | -8.396428 |
| Price To Sales Trailing12 Months | -98.384964 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.449 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0936 |
| Regular Market Change Percent | -16.6016 |
| Regular Market Day High | 0.5651 |
| Regular Market Day Low | 0.47 |
| Regular Market Day Range | 0.47 - 0.5651 |
| Regular Market Open | 0.5601 |
| Regular Market Previous Close | 0.5638 |
| Regular Market Price | 0.4702 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 9,585,303 |
| Return On Assets | -1.43166 |
| Revenue Growth | -0.994 |
| Revenue Per Share | -0.014 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 243,447,554 |
| Shares Percent Shares Out | 0.131 |
| Shares Short | 31,896,591 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 32,910,138 |
| Short Name | Outlook Therapeutics, Inc. |
| Short Percent Of Float | 0.1388 |
| Short Ratio | 7.1 |
| Source Interval | 15 |
| State | NJ |
| Symbol | OTLK |
| Target High Price | 10.5 |
| Target Low Price | 1.6 |
| Target Mean Price | 5.025 |
| Target Median Price | 4.0 |
| Total Cash | 11,242,068 |
| Total Cash Per Share | 0.046 |
| Total Debt | 18,431,144 |
| Total Revenue | -1,163,481 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.691625 |
| Two Hundred Day Average Change | -0.221425 |
| Two Hundred Day Average Change Percent | -0.3201518 |
| Type Disp | Equity |
| Volume | 9,585,303 |
| Website | https://outlooktherapeutics.com |
| Zip | 8,830 |